Multiple Myeloma: International Myeloma Foundation : research : myeloma matrix

Myeloma Matrix - Drugs In Development or Recently-Approved

The Myeloma Matrix lists drugs currently under development and tracks them from discovery to approval.

Clicking on the drug names shown in red will retrieve relevant clinical trials.

share |

Myeloma Matrix

expand all

collapse all

FDA Approved

Phase III

Phase II/III

Phase II

Phase I/II

	COMPANY	INDICATION
Amplimexon imexon Amplimexon imexon	AmpliMed Corp	Rapamycin analog administered IV. STUDY COMPLETED.
AR-42 (formerly HDAC-42) AR-42 (formerly HDAC-42)	Arno Therapeutics	Orally available inhibitor of both histone and non-histone deacetylation proteins for patients with advanced or relapsed MM, CLL, or lymphoma
ARRY-520 ARRY-520	Array BioPharma	Novel kinesin spindle protein inhibitor for patients with relapsed or refractory mm or plasma cell leukemia who have already received at least two previous treatments.
BHQ880 BHQ880	Novartis	A study to assess BHQ880, an anti-DKK-1 antibody, in combination with zoledronic acid in relapsed/refractory myeloma.
BIW-8962 BIW-8962	BioWa, Incorporated	Dosing study of monoclonal antibody that targets the GM-2 ganglioside (expressed at high levels on the surface of mm cells) followed by efficacy study.
Brostallicin PNU-166196 Brostallicin PNU-166196	Pharmacia and NCI	For the treatment of recurrent or refractory multiple myeloma.
Busulfex(R) busulfan Busulfex(R) busulfan	Otsuka America Pharmaceutical	For use in auto transplant for patients 65 or older or those with renal insufficiency
CNTO 328 CNTO 328	Centocor	Monoclonal antibody to IL-6
elotuzumab HuLuc63 elotuzumab HuLuc63	Facet Biotech	Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
HuMax-CD38 (human IgG1,k antibody) HuMax-CD38 (human IgG1,k antibody)	Genmab A/S	Antibody to the CD 38 molecule, which is highly expressed on the surface of mm cells.
milatuzumab hLL1 milatuzumab hLL1	Immunomedics	Open-label, multi-center study of a humanized monoclonal antibody to the CD74 myeloma cell surface antigen for patients with recurrent or refractory multiple myeloma who have failed at least 2 prior standard systemic treatments.
MLN9708 MLN9708	Millennium	Open-label, dose-escalation, Phase 1/2 study of the oral form of MLN9708, a second-generation proteasome Inhibitor, in adult patients with relapsed and refractory mm
noscapine CB3304 noscapine CB3304	Cougar Biotechnology	Oral alkaloid derived from opium; trial for relapsed/refractory mm.
Plaquenil hydroxychloroquine Plaquenil hydroxychloroquine	NCI	FDA-approved anti-inflammatory drug for malaria, lupus, and rheumatoid arthritis in trials with Velcade for rel/ref mm.
Torisel™ temsirolimus CCI-779 Torisel™ temsirolimus CCI-779	Wyeth	m-TOR inhibitor in combination with bortezomib (Velcade) for rel/ref MM.
Tysabri® natalizumab Tysabri® natalizumab	Biogen Idec	Monoclonal antibody for the treatment of relapsed/refractory mm
VELCADE® bortezomib PS-341, LDP-341, MLN-341 VELCADE® bortezomib PS-341, LDP-341, MLN-341	Millennium: The Takeda Oncology Company	As maintenance therapy after auto-transplant in patients with intermediate or advanced MM.

Phase IB

Phase I

	COMPANY	INDICATION
ACE-041 ACE-041	Acceleron	To evaluate the safety and tolerability of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma
anti-KIR mAb 1-7F9 anti-KIR mAb 1-7F9	Novo Nordisk	Safety and tolerability study for patients with relapsed/refractory MM.
AP24534 AP24534	Ariad Pharmaceuticals	Maximum tolerated dose of AP24534 in CML and other hematological malignancies.
ARRY-614 ARRY-614	Array BioPharma	Orally active p38/Tie2 inhibitor in dose escalation trial.
AVN994 AVN994	Avalon Pharmaceuticals	Open-label, repeat-dose escalation, safety and tolerability trial for patients with advanced hematological malignancies. STUDY COMPLETED.
BB-10901 BB-10901	ImmunoGen, Inc.	Targets and kills cancer cells that express the CD 56 antigen. A humanized monoclonal antibody coupled with a cancer-killing agent. (huN901-DM1huN901-N2'-Deacetyl-N2-(2-Mercapto-1-oxopropyl)-Maytasine)
BI-505 BI-505	BioInvent International (Sweden)	Dose escalation study of a monoclonal antibody to CD54
BT062 BT062	Biotest Pharmaceuticals Corporation	Safety and dose-determing study of BT062 in patients with relapsed or refractory multiple myeloma. (maytansinoid-conjugated anti-myeloma monoclonal antibody BT062)
CX-4945 CX-4945	Cylene Pharmaceuticals	Multi-center, open-label, dose-escalation, safety, pharmacokinetic and pharmacodynamic study; administered orally. Site contact: J. Shelby, RN, 970-212-7609, Front Range Cancer Specialists, Fort Collins, CO, PI Robert Marschke, MD
elotuzumab HuLuc63 elotuzumab HuLuc63	Facet Biotech	Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma. STUDY COMPLETED.
ENMD-2076 ENMD-2076	EntreMed	Oral selective kinase inhibitor currently in phase I for refractory cancer.
fenretinide 4-HPR fenretinide 4-HPR	California Cancer Consortium; NCI	Intravenous chemotherapy agent in a safety and tolerability study for patients with relapsed or refractory hematologic cancer
flavopiridol HMR 1275, L86-8275 flavopiridol HMR 1275, L86-8275	NCI	Study of bortezomib and flavopiridol in patients with recurrent/refractory B-cell neoplasms to determine maximum tolerated dose, safety, and efficacy.
fluphenazine fluphenazine	Immune Control, Inc.	Serotonin antagonist for relapsed/refractory mm.
GRN163L (telomerase inhibitor GRN13L) GRN163L (telomerase inhibitor GRN13L)	Geron Corporation	Two trials running concurrently, one with, and one without Velcade
IMGN901 IMGN901	ImmunoGen, Inc.	CD-56 monoclonal antibody conjugated with maytansinoid, a toxin that selectively targets cancer cells
IPI-504 IPI-504	Infinity Pharmaceuticals	Safety and efficacy trial of Heat Shock Protein 90 inhibitor on patients with relapsed/refractory mm. Study completed.
KW-2478 KW-2478	Kirin Co Ltd.	Novel Hsp90 antagonist in dose escalation study in Japan.
MDX-1097 MDX-1097	Immune System Therapeutics Limited	Open-label safety and efficacy study in the treatment of previously treated kappa light chain-restricted mm. Trial was completed in Dec. 2009; no phase II trial yet open.
MLN4924 MLN4924	Millennium Pharmaceuticals	Open-label, dose-escalation study of MLN4924, a novel inhibitor of Nedd8 activating enzyme, in adult patients with lymphoma or multiple myeloma Trial site locations: Winship Cancer Institute, Emory University, Atlanta, GA; U of Texas MD Anderson Cancer Center, Houston, TX
noscapine CC 3304 noscapine CC 3304	Cougar Biotech	Dose escalation and safety study for patients with relapsed/refractory multiple myeloma
palifermin palifermin	Amgen, Inc	Supportive care to help prevent mucositis after HDT.
pyroxamide pyroxamide	National Cancer Institute	Histone deacytelase (HDAC) inhibitor for advanced malignancies.
Revlimid® lenalidomide CC-5013 Revlimid® lenalidomide CC-5013	Celgene Corporation	Combined with various other drugs in relapsed/refractory MM.
salinosporamide NPI-0052 salinosporamide NPI-0052	Nereus Pharmaceuticals	A single-agent, dose escalation study for patients with relapsed or relapsed/refractory multiple myeloma. Sites: Dana-Farber Cancer Institute, Ohio State University, Roswell Park Cancer Institute, University of Chicago and University of Michigan.
SCH 727965 SCH 727965	Schering-Plough	Cyclin-dependent kinase inhibitor.
SNS-032 SNS-032	Sunesis	Dose-excalation study to examine the safety and tolerability, as well as preliminary anti-tumor activity, of a novel targeted inhibitor of CDKs 2, 7 and 9, in patients with B-cell malignancies.
Torisel™ temsirolimus CCI-779 Torisel™ temsirolimus CCI-779	Wyeth	m-TOR inhibitor in combination with lenalidomide (Revlimid) for rel/ref MM.
VELCADE® bortezomib PS-341, LDP-341, MLN-341 VELCADE® bortezomib PS-341, LDP-341, MLN-341	Millennium: The Takeda Oncology Company	Trials combining VELCADE® with other agents in relapse setting.
XL228 (tyrosine kinase inhibitor XL228) XL228 (tyrosine kinase inhibitor XL228)	Exelixis	Dose escalation trial of small molecule inhibitor of IGF1R and SRC for patients with solid tumors, lymphoma, or multiple myeloma.
Zarnestra™ tipifarnib FTI R115777, R115777 Zarnestra™ tipifarnib FTI R115777, R115777	Johnson & Johnson	Multi-center trial to determine optimal dosing of Velcade (bortezomib) in combination with Zarnestra (tipifarnib) for the treatment of relapsed/refractory mm.
Zolinza vorinostat/SAHA MK0683 Zolinza vorinostat/SAHA MK0683	Merck	HDAC inhibitor that has already been approved for cutaneous T-Cell lymphoma and is now being studied in myeloma in combination with bortezomib (Velcade).

Pre-Clinical

	COMPANY	INDICATION
1D09C3 1D09C3	GPC Biotech, AG	Fully human anti-HLA-DR antibody; its anti-mm activity is enhanced by IFN-gamma.
5AHQ (5-amino-8-hydroxyquinoline) 5AHQ (5-amino-8-hydroxyquinoline)	Princess Margaret Hospital	Novel chemical proteasome inhibitor induced cell death in 9/9 mm cell lines.
ABT737 ABT737	Abbott	Small molecule Bcl-2 inhibitor that also overcomes resistance to proteasome inhibition.
Actemra® tocilizumab injection Actemra® tocilizumab injection	Chugai Pharmaceutical Company; Hoffman-La Roche	Anti-human IL-6 receptor monoclonal antibody approved for treatment of Castleman’s Disease being studied in rheumatoid arthritis, Crohn’s Disease, and myeloma.
Ad-p53/GM-CSF/B7-1 immunotherapy Ad-p53/GM-CSF/B7-1 immunotherapy	Beijing Institute of Radiation Medicine	Recombinant adenovirus carrying human wild-type p53, granulocyte-macrophage colony-stimulating factor, and B7-1 genes.
Alimta® pemetrexed Alimta® pemetrexed	Eli Lilly	FDA-approved antifolate chemo agent (for second-line therapy of non-small cell lung cancer) demonstrates potent anti-myeloma effect on cell lines and fresh cells from patients resistant to conventional agents
AMG523 AMG523	Amgen	B-cell activating factor (BAFF) inhibitor active in MM cell lines.
anti-beta2-microglobulin monoclonal antibodies (anti-B2M mAbs) anti-beta2-microglobulin monoclonal antibodies (anti-B2M mAbs)	MD Anderson Cancer Center	Strong apoptotic effect on myeloma cells suppports potential use as therapeutic agents.
anti-CD 32B monoclonal antibody anti-CD 32B monoclonal antibody	MacroGenics	Monoclonal antibody against low-affinity Fc receptor for use in the treatment of hematologic cancers.
anti-DKK1 anti-DKK1	UAMS	DKK1 neutralizing antibodies reduce osteolytic bone resorption, increase bone formation, and help control myeloma growth in lab mice.
antigen-loaded dendritic cell vaccine antigen-loaded dendritic cell vaccine	National Cancer Institute and Aastrom Biosciences	Idiotype vaccination following allogeneic transplant.
AP23841 AP23841	Ariad Pharmaceuticals	Small molecule inhibitor of osteoclasts.
APOMINE™ SR-45023A APOMINE™ SR-45023A	ILEX	Bisphosphonate ester.
AQX-MN100 AQX-MN100	Aquinox Pharmaceuticals	Sea sponge compound that inhibits immune and blood cell activation.
AT-101 AT-101	Ascenta Therapeutics, Inc.	Orally available pan-Bcl-2 inhibitor demonstrated significant anti-myeloma activity in vitro at Mayo Rochester.
AT9283 AT9283	Astex Therapeutics	Small molecule multi-targeted kinase inhibitor induces anti-myeloma activity via aurora kinase and STAT3 inhibition
ATL313 ATL313	CombinatoRx, Inc.	Adenosine A2A agonist compund used in combination therapy for the treatment of mm and other B-cell cancers.
BAY 73-4056 BAY 73-4056	Bayer	Orally available multi-kinase inhibitor active in all MM cell lines.
BIO 5192 BIO 5192	Biogen	Small molecule inhibitor VLA-4 being studied for mobilization of hematopoietic stem cells
BiovaxID™ BiovaxID™	Biovest International/Accentia Biopharmaceuticals	Personalized, anti-idiotype vaccine for B-cell-related blood cancers.
BIRB 796 BIRB 796	Buchringer Ingelheim Pharmaceuticals	p38 MAPK inhibitor that overcomes drug resistance in the bone marrow microenvironment
bisphosphonate conjugates bisphosphonate conjugates	MBC Pharma	Compound drugs that couple a bisphosphonate with an anticancer agent to target bone and/or surrounding tissue.
BiTE antibody BiTE antibody	Boehringer Ingelheim, Micromet	CD3 antibody coupled with an antibody that is being targeted to a cell surface receptor on the myeloma cell.
BLyS/rGel BLyS/rGel	Targa Therapeutics	Fusion protein of an antibody tethered to a toxin for the potential treatment of myeloma and autoimmune diseases.
BMS-214662 BMS-214662	Bristol-Myers Squibb	Farnesyltransferase inhibitor.
capsaicin capsaicin	MD Anderson Cancer Center	Spicy component of hot pepper that preferentially induces apoptosis in MM cells. Low-dose combined capsaicin, thalidomide, and bortezomib triggered synergistic cytotoxicity.
CD32B Mab CD32B Mab	MacroGenics, Inc.	Monoclonal antibody targeted against CD32B; may have therapeutic potential in B-cell malignancies (NHL, CLL, MM).
CD74-DOX conjugate (anti-CD74 monoclonal antibody conjugated with doxorubicin) CD74-DOX conjugate (anti-CD74 monoclonal antibody conjugated with doxorubicin)	Immunomedics, Inc.	Therapy targeted to CD74-expressing MM cell lines.
CDDO-Im (CDDO-Imidazolide) CDDO-Im (CDDO-Imidazolide)	Johns-Hopkins and Dartmouth	A synthetic version of oleanolic acid, found in olive leaf extracts, which triggers apoptosis in mm cells.
CEP-18770 CEP-18770	Cephalon	Novel, orally active proteasome inhibitor.
CGEN-928 CGEN-928	Compugen Ltd.	Membrane protein that is expressed broadly on MM tumor cells and is has potential use as a drug target for MM.
chaetocin chaetocin	Mayo Clinic	A fungal toxin that demonstrates potent anti-myeloma activity through oxidative stress and consequent apoptosis induction.
ciclopirox olamine (CPX) off patent ciclopirox olamine (CPX) off patent		Prescription medication for fungal infections tested and found to have anti-myeloma and anti-leukemia activity.
cKap cKap	PacMab Ltd.	Chimeric version of the murine antibody, mKap, that induces apoptosis in all myeloma cell lines shown to express the surface antigen KMA. cKap is highly effective in inducing antigen-dependent cellular cytotoxicity.
CP-533,536 CP-533,536	Pfizer	Triggers healing of fractures and bone defects.
CPHPC CPHPC	Royal Free Hospital, London	Binds to serum amyloid P compound to prevent amyloid deposition.
CPS11 & CPS49 CPS11 & CPS49	Celgene Corporation	Thalidomide analogs developed at University of Leipzig and licensed to Celgene.
CRB-15 (IL-15 cytokine receptor blocker) CRB-15 (IL-15 cytokine receptor blocker)	Roche, Cardion AG	Targeted against IL-15 receptor to prevent transplant rejection.
cyclopamine; Hedgehog Pathway inhibitor IPI-926 cyclopamine; Hedgehog Pathway inhibitor IPI-926	Infinity Pharmaceuticals	Orally available derivative of cyclopamine inhibits the Hedgehog Pathway (which takes its name from an intercellular signaling molecule). Hedgehog pathway plays an important role in cancer stem cells.
CYT997 CYT997	Cytopia, Ltd.	novel tubulin polymerization inhibitor that synergizes with bortezomib for potent anti-MM activity.
degrasyn degrasyn	Callisto Pharmaceuticals	Small molecule that induces degradation of c-Myc in mm and other tumor cell lines.
DMAPT (dimethylamino- parthenolide) DMAPT (dimethylamino- parthenolide)	Indiana University	NFkB inhibitor demonstrated excellent efficacy in preclinical mouse models of mm alone and in combination with bortezomib and with lenolidomide.
DOM 1112 DOM 1112	Domantis	Dual targeting domain antibody (dAb) directed against CD38 and CD138 for the potential treatment of mm.
EGCG (epigallocatechin -3-gallate) EGCG (epigallocatechin -3-gallate)	Dana-Farber, VA Boston	Polyphenol extracted from green tea induces growth arrest and apoptosis in myeloma cells.
ENMD-981693 ENMD-981693	EntreMed	Oral, multi-target aurora kinase-angiogenesis inhibitor that demonstrates tumor regression and significant growth inhibition in mm xenografts
Evista® raloxifene Evista® raloxifene	University of Liege	Selective estrogen receptor modulator that induces myeloma cell cycle arrest and apoptosis.
factor 5A (eukaryotic translation initiation factor 5A1) factor 5A (eukaryotic translation initiation factor 5A1)	Senesco Technologies, Inc.	Controls formation of proteins required for cell death.
flubendazole flubendazole	Janssen	Approved anti-parasitic (antihelmintic) drug with previously unrecognized preclinical activity in leukemia and myeloma.
fludelone (Flu) fludelone (Flu)	Memorial Sloan-Kettering Cancer Center	Synthetic epothilone that eradicates myeloma cells grafted in mice.
ganoderma ganoderma	Cedars-Sinai Medical Center; University Hospital, Freiburg	Mushroom extract with antiproliferative activity against leukemia, lymphoma, and myeloma.
geldanamycin (GA) geldanamycin (GA)	National Cancer Institute	Inhibits proteins that protect cancer cells from effects of therapy.
GX15-070 GX15-070	Gemin X Biotechnologies, Inc.	Pan-Bcl-2 inhibitor found to induce apoptosis in 12/12 myeloma cell lines tested by A. Keith Stewart et al. at Mayo Scottsdale.
halofuginone halofuginone	Dana-Farber Cancer Institute	Orally available synthetic derivative of quinazolinone alkaloid induces mm cell death and improves survival in mice.
highly purified hematopoietic stem cells (HSCs) highly purified hematopoietic stem cells (HSCs)	Cellerant Therapeutics, Inc.	Eliminates cancer cells and T-cells from HSCs used in transplant.
honokiol (HNK) honokiol (HNK)	Dana-Farber Cancer Institute	Traditionally used in Chinese and Japanese medicine and derived from magnolia; cytotoxic to myeloma cell lines.
HSP90i HSP90i	Novartis	Novel orally bioavailable heat shock protein 90 inhibitor that induces apoptosis and synergizes with bortezomib in human myeloma cells
imexon imexon	University of Arizona	Induces apoptosis, oxidative stress, and mitochondrial alterations in myeloma cells.
IMMU-110 IMMU-110	Immunomedics, Inc.	Humanized monoclonal antibody conjugated with doxorubicin and targeted to CD74 antigen.
IMMU-114 IMMU-114	Immunomedics, Inc.	anti-HLA-DR humanized monoclonal antibody that is toxic to cells of several hematologic malignancies, including mm
indolinone BIBF 1000 indolinone BIBF 1000	Boehringer Ingelheim Pharma GmbH	Targeted kinase inhibitor that induces apoptosis in t(4;14)-positive cell lines.
ISIS 345794 ISIS 345794	Isis Pharmaceuticals	Antisense drug targeting STAT-3
ispinesib ispinesib	Cytokinetics	Novel inhibitor of kinesin spindle protein (KSP) induces cell death in MM cells, and overcomes resistance to conventional drugs and novel agents.
JNJ-26481585 JNJ-26481585	Johnson and Johnson	HDAC inhibitor that reduces tumor load and paraprotein secretion and increases bone volume and trabecular number in combination with Velcade.
JS-K (JS-kappa) JS-K (JS-kappa)	Dana-Farber Cancer Institute	Prodrug designed to release nitric oxide that shows significant cytotoxicity in both conventional therapy-sensitive and -resistant MM cell lines.
KOS-2484 KOS-2484	Kosan Biosciences	Third-generation Hsp-90 inhibitor.
KRN5500 KRN5500	Kirin Co Ltd.	Exerts anti-mm effects by impairing both mm cells and osteoclasts in mice.
KT-5720 KT-5720	Chaim Sheba Medical Center (Israel)	Reverses multidrug resistance in cells from patients with MM. Good candidate for combination therapy.
L-NAME (N-G-nitro-L- arginine methyl ester ) L-NAME (N-G-nitro-L- arginine methyl ester )	Kumamoto University (Japan)	Nitric oxide synthase inhibitor.
LBW242 LBW242	Novartis; Dana-Farber	A low molecular weight second mitochondria-derived activator of caspases (smac) that promotes apoptosis in myeloma cells resistant to conventional and bortezomib therapies.
LS 104 LS 104	LymphoSign	Kinase inhibitor that is active in myeloma in vitro.
mAb, C11C1 mAb, C11C1	Temple University School of Medicine	Monoclonal antibody to kininogen may improve the efficacy of conventional mm treatment with minimal side effects.
mAb, ICAM-1 mAb, ICAM-1	Abiogen	Monoclonal antibody being evaluated in Italy for the potential treatment of myeloma.
manumycin manumycin	University of Bari, Italy	A natural farnesyltransferase inhibitor prevents proliferation and induces apoptosis of mm cells.
MGCD0103 MGCD0103	MethylGlene Inc.	HDAC inhibitor active against myeloma cell lines in combination with interferon alpha.
MK-0457 MK-0457	Merck (VX-680)	Pan-aurora kinase inhibitor that synergistically potentiates Apo2L/Trail cytotoxicity in mm cells sensitive and resistant to bortezomib
MLN3897 (formerly AVE9897) MLN3897 (formerly AVE9897)	Millennium: The Takeda Oncology Company	Novel specific antagonist of chemokine receptor CCR1 for the treatment of osteolytic bone disease in myeloma.
MLN8237 MLN8237	Millennium: The Takeda Oncology Company	Small molecule Aurora-A kinase inhibitor induces apoptosis in mm cell lines.
MMF (mycophenolate mofetil) MMF (mycophenolate mofetil)	University of Maryland	IMP dehydrogenase inhibitor active against myeloma cells in vitro.
MOR202 MOR202	MorphoSys AG	Antibody targeting molecule CD38
MyelomaCide_ Y-90 MyelomaCide_ Y-90	Immunomedics, Inc.	Y-90-labeled antibody.
nifuroxazide nifuroxazide	Dana-Farber Cancer Institute	Potent inhibitor of STAT signaling; shows cytotoxicity against mm cells that rely on STAT3 for survival.
nocodazole nocodazole	University of Pittsburgh	Drug for intestinal worms inhibits cytokines necessary for myeloma cell growth and causes mm cell death in vitro.
NPI-2358 NPI-2358	Nereus Pharmaceuticals	Novel vascular-disrupting agent (VDA) with anti-angiogenic and anti-tumor activity against mm cells, without significant toxicity in normal cells. Is already in a phase II trial in non-small cell lung cancer.
NVP-AUY922 NVP-AUY922	Novartis	Novel heat shock protein 90 inhibitor.
NVP-LAQ824 NVP-LAQ824	Novartis	Histone deacetylase inhibitor.
parthenolide (PTL) parthenolide (PTL)	Indiana University; Sapporo Medical University	Extract from feverfew that strongly induces apoptosis in MM cell lines
patupilone (epothilone B) EPO906 patupilone (epothilone B) EPO906	Novartis	A novel chemo agent that inhibits growth and survivial of myeloma cells,including those resistant to conventional chemo.
PD173074 PD173074	GlaxoSmithKline	Small molecule fibroblast growth factor receptor inhibitor that inhibits the growth of two t(4;14)-positive MM lines.
PHI 380 PHI 380	Parker Hughes Cancer Center	Phenylarsonic acid derivative that causes apoptotic death to cell lines of various cancers, including myeloma.
PKC412 PKC412	Novartis	Tyrosine kinase inhibitor that targets fibroblast growth factor.
PKF115-584 PKF115-584	Dana-Farber Cancer Institute	Small molecule that blocks the beta-catenin/TCF protein complex.
PPAR-gamma ligands (15d-PGJ2 and ciglitazone) PPAR-gamma ligands (15d-PGJ2 and ciglitazone)	University of Rochester	Antidiabetic therapies that induce MM cell apoptosis
PPP (picropodophyllin) PPP (picropodophyllin)	Vrije University of Brussels	Cyclolignan that inhibits IGF-1R tyrosine kinase and reduces proliferation and angiogenesis of MM cells.
PRO-001 PRO-001	Prochon Biotech Ltd.	Anti-FGFR3 neutralizing antibody that is cytotoxic to t(4;14)-positive MM cells.
PS 1145 PS 1145	Millennium: The Takeda Oncology Co.	kappaB kinase (IKK) inhibitor.
R-etodolac SDX-101 R-etodolac SDX-101	Salmedix	Single component of the anti-inflammatory drug etodolac; circumvents drug resistance in MM cell lines.
recombinant human Mannose-Binding Lectin (rhMBL) recombinant human Mannose-Binding Lectin (rhMBL)	Enzon	For the treatment of severe infections in patients with mm and others who are MBL deficient.
Reolysin® reovirus (oncolytic viral therapy) Reolysin® reovirus (oncolytic viral therapy)	Oncolytics Biotech, Inc.	Reovirus used as purging agent during auto transplant.
reversine [2-(4- Morpholinoanilino)-6- cyclohexylaminopurine] reversine [2-(4- Morpholinoanilino)-6- cyclohexylaminopurine]	Dana Farber Cancer Institute	Small molecule that may represent a distinct class of agents with therapeutic potential for specific subsets of MM.
RGB 286638 RGB 286638	GPC Biotech AG	Multi-targeted small molecule inhibitor induces cell death and prolongs survival in mouse model.
rhPDGF rhPDGF	BioMimetic Therapeutics	Recombinant protein for the treatment of osteonecrosis of the jaw.
SAR650984 SAR650984	ImmunoGen, Sanofi-Aventis	Anti-CD38 MAb completely prevented all tumor growth in mice.
Sarasar™ lonafarnib SCH66336 Sarasar™ lonafarnib SCH66336	Schering-Plough	Farnesyltransferase inhibitor (FTI)
SDX-308 SDX-308	Salmedix	More potent analog of the non-steroidal anti-inflammatory drug SDX-101 (R-etodolac); inhibits osteoclast formation and myeloma cell proliferation.
seliciclib (R-roscovitine) CYC202 seliciclib (R-roscovitine) CYC202	Cyclacel	Oral cyclin dependent kinase inhibitor.
skeletally targeted proteasome inhibitors (bone-targeting nanocapsules) skeletally targeted proteasome inhibitors (bone-targeting nanocapsules)	US Department of Defense, Southwest Research Institute and UT Health Science Center	Targeting proteasome inhibitors to myeloma lesions in bone via nanocapsules.
SNS-01 SNS-01	Senesco Technologies, Inc.	Animal studies completed with combination therapy of Factor5A and an siRNA against Factor5A.
SNX-2112 SNX-2112	Pfizer (which bought Serenex in March ‘08)	Orally available small molecule Hsp90 inhibitor that inhibits MM cell growth.
SRI16388 SRI16388	Stanford Research Institute	Orally available anti-angiogenic molecule that kills myeloma cells by blocking their ability to survive in a hypoxic microenvironment.
StemEx® StemEx®	Gamida Cell	Hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy.
SU5402 SU5402	Sugen	Fibroblast growth factor receptor inhibitor that inhibits the growth of two t(4;14)-positive MM lines.
Tc-99m-MIBI (technecium-99m 2-methoxy- isobutylisonitrile) Tc-99m-MIBI (technecium-99m 2-methoxy- isobutylisonitrile)	Uludag University (Turkey)	Sensitive imaging (scanning) technique.
TG101209 TG101209	TargeGen Inc.	Novel JAK2 inhibitor with significant activity in vitro in mm. Associated with preferential cytotoxicity for CD45+ myeloma cells
TH-302 TH-302	Threshold Pharmaceuticals	Hypoxia-activated prodrug that triggers apoptosis in mm cells.
thioredoxin antisense molecules thioredoxin antisense molecules	Lorus Therapeutics, Inc.	Reduces level of thioredoxin.
TRAIL-RlmAb TRAIL-RlmAb	Human Genome Sciences	Binds to TRAIL, a TNF. Cleared by FDA for Phase I trial.
treosulfan treosulfan	University of Muenchen	Alkylating agent.
trichostatin A (TSA) trichostatin A (TSA)	University of Maryland	Histone deacetylase inhibitor that sensitizes TRAIL-resistant myeloma cells to remove the obstacles to programmed cell death.
triciribine phosphate monohydrate, TCN-P VQD-002 triciribine phosphate monohydrate, TCN-P VQD-002	VioQuest Pharmaceuticals	Small molecule anticancer compound that inhibits AKT (protein kinase B)
tubacin (aggresome inhibitor) tubacin (aggresome inhibitor)	Dana-Farber Cancer Institute and Broad Institute of MIT	Blocks the function of histone deacetylase 6; used with bortezomib as an alternative protein disposal inhibitor
UCN-01 (7-hydroxystaurosporine) UCN-01 (7-hydroxystaurosporine)	Keryx Biopharmaceuticals	Novel multi-kinase inhibitor that shows activity against myeloma cells in combination with farnesyltransferase inhibitors or statins.
ULBP2-BB4 ULBP2-BB4	University Hospital Cologne	Novel recombinant bispecific protein that strongly activates primary NK cells.
VE465 VE465	Vertex/Merck	Aurora kinase inhibitor that is active in vitro against MM cell lines and/or primary MM tumor cells resistant to various anti-myeloma therapies.
VEL-0230 VEL-0230	Velcura Therapeutics, Inc.	New chemical entity that both inhibits osteoclastogenesis and promotes osteoblastogenesis.
VSV (Δ51)-NIS (recombinant vesicular stomatitis virus) VSV (Δ51)-NIS (recombinant vesicular stomatitis virus)	Mayo Clinic and Ottowa Health Research Institute	Novel radiovirotherapy combination with VSV(Δ51)-NIS plus iodide-131 that is effective in vitro and in vivo.
VX-944 VX-944	Vertex Pharmaceuticals licensed to Avalon Pharmaceuticals	Enzymatic, small molecule inhibitor of inosine monophosphate dehydrogenase that inhibits in vitro growth of human mm.
zalypsis zalypsis	PharmaMar (Marid, Spain)	Marine-derived alkaloid with potent in vivo and in vitro anti-myeloma activity.